Business, energy, technology, markets and global industry news from Business News Today

ATOMIC

PharmaDeviceNews ATOMIC
Infographic showing Akeso’s Phase III cadonilimab trial in colon cancer, with 386 patients planned and recurrence outcomes highlighted as a central study focus.
Pharma & Biotech

Cadonilimab delivered 84.6% complete responses in an earlier study. Can Akeso prove lasting benefit?

Akeso starts Phase III cadonilimab testing in colon cancer, with 386 patients planned and recurrence outcomes central to its clinical strategy.

Read More
Infographic showing FDA approval of Tecentriq for adjuvant stage III dMMR colon cancer, highlighting the ATOMIC trial and a 50% reduction in recurrence or death risk.
Pharma & Biotech

Roche Tecentriq FDA approval expands treatment for stage III dMMR colon cancer

FDA approval moves Tecentriq into adjuvant stage III dMMR colon cancer after ATOMIC showed a 50% reduction in recurrence or death risk.

Read More
Representative image: An oncologist discusses colon cancer treatment options with a patient, reflecting Genentech’s Tecentriq Priority Review and the growing role of immunotherapy in stage III dMMR/MSI-H colon cancer care.
Pharma & Biotech

Why Genentech’s Tecentriq Priority Review could change adjuvant colon cancer treatment

Find out how Genentech’s Tecentriq Priority Review could reshape adjuvant treatment for stage III dMMR/MSI-H colon cancer.

Read More